HOP S. TRAN CAO to Neoadjuvant Therapy
This is a "connection" page, showing publications HOP S. TRAN CAO has written about Neoadjuvant Therapy.
Connection Strength
2.335
-
Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Surgery. 2019 06; 165(6):1144-1150.
Score: 0.514
-
Exceptional pathologic response to preoperative therapy in the context of mutational profiling for colorectal liver metastases. J Gastrointest Surg. 2024 Jul; 28(7):1181-1184.
Score: 0.185
-
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma. Ann Surg Oncol. 2023 12; 30(13):7960-7965.
Score: 0.177
-
Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB (Oxford). 2023 04; 25(4):472-480.
Score: 0.169
-
Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection. Ann Surg Oncol. 2022 Aug; 29(8):5156-5164.
Score: 0.160
-
Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol. 2021 Oct; 28(11):6725-6735.
Score: 0.148
-
ASO Author Reflections: Role of Neoadjuvant Therapy in Surgically Resectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2021 10; 28(11):6736-6737.
Score: 0.147
-
Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet? JAMA Oncol. 2020 08 01; 6(8):1163-1164.
Score: 0.142
-
National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. J Surg Res. 2019 05; 237:41-49.
Score: 0.128
-
Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. J Surg Res. 2018 06; 226:15-23.
Score: 0.120
-
Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery. 2017 09; 162(3):557-567.
Score: 0.115
-
Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
Score: 0.089
-
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma. Oncology. 2025; 103(6):490-497.
Score: 0.048
-
Understanding the association between clinical staging accuracy, treatment response, and survival among gastric cancer patients through Bayesian analysis. J Surg Oncol. 2022 Nov; 126(6):986-994.
Score: 0.041
-
Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Ann Surg. 2022 03 01; 275(3):415-421.
Score: 0.040
-
Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis. Ann Surg Oncol. 2021 Jun; 28(6):3186-3195.
Score: 0.036
-
Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma. J Natl Compr Canc Netw. 2019 02; 17(2):161-168.
Score: 0.032
-
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
Score: 0.022
-
Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26.
Score: 0.022